.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,846,090

« Back to Dashboard

Claims for Patent: 8,846,090

Title:Matrix for sustained, invariant and independent release of active compounds
Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.
Inventor(s): Brogmann; Bianca (Ulm, DE), Muhlau; Silke (Biberach, DE), Spitzley; Christof (Eibtal, DE)
Assignee: Euro-Celtique S.A. (Luxembourg, LU)
Application Number:13/348,617
Patent Claims: 1. An oral pharmaceutical formulation comprising: at least one opioid agonist selected from oxycodone and pharmaceutically acceptable salts thereof; at least one opioid antagonist selected from naloxone and pharmaceutically acceptable salts thereof; and a diffusion matrix containing the at least one opioid agonist and the at least one opioid antagonist and comprising ethylcellulose and at least one fatty alcohol; wherein the matrix is configured to provide sustained, invariant, and independent release of the opioid agonist and the opioid antagonist; and wherein the fatty alcohol is present in 5-30% by weight of the total formulation.

2. The pharmaceutical formulation of claim 1, wherein the fatty alcohol is selected from lauryl alcohol, myristyl alcohol, stearyl alcohol, cetylstearyl alcohol, ceryl alcohol, and cetyl alcohol.

3. The pharmaceutical formulation of claim 1, wherein the fatty alcohol is stearyl alcohol.

4. The pharmaceutical formulation of claim 1, wherein the opioid agonist is oxycodone hydrochloride.

5. The pharmaceutical formulation of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 5 to 50 mg.

6. The pharmaceutical formulation of claim 1, wherein the opioid antagonist is naloxone hydrochloride.

7. The pharmaceutical formulation of claim 1, wherein the naloxone or pharmaceutically acceptable salt thereof is present in an amount ranging from 1 to 40 mg.

8. The pharmaceutical formulation of claim 1, wherein: the opioid agonist is oxycodone hydrochloride; and the opioid antagonist is naloxone hydrochloride.

9. The pharmaceutical formulation of claim 1, wherein: the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 10 to 150 mg; and the naloxone or pharmaceutically acceptable salt thereof is present in an amount ranging from 1 to 50 mg.

10. The pharmaceutical formulation of claim 9, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 10 to 80 mg.

11. The pharmaceutical formulation of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 5 to 50 mg.

12. The pharmaceutical formulation of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio ranging from 25:1 to 1:1.

13. The pharmaceutical formulation of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio ranging from 5:1 to 1:1.

14. The pharmaceutical formulation of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio of 5:1, 4:1, 3:1, 2:1, or 1:1.

15. The pharmaceutical formulation of claim 1, wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio of 2:1.

16. The pharmaceutical formulation of claim 1, wherein the ethylcellulose is present in 1-15% by weight of the total formulation.

17. The pharmaceutical formulation of claim 1, wherein the ethylcellulose is present in 5-9% by weight of the total formulation.

18. The pharmaceutical formulation of claim 1, wherein the fatty alcohol is present in 15-20% by weight of the total formulation.

19. The pharmaceutical formulation of claim 1, wherein the fatty alcohol is present in 10-25% by weight of the total formulation.

20. The pharmaceutical formulation of claim 1, wherein the ethylcellulose is present in 1-15% by weight of the total formulation; the fatty alcohol is stearyl alcohol and is present in 10-25% by weight of the total formulation; and the oxycodone or pharmaceutically acceptable salt thereof and is present in an amount ranging from 10 to 80 mg; wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio of 2:1.

21. The pharmaceutical formulation of claim 20, wherein: the opioid agonist is oxycodone hydrochloride; and the opioid antagonist is naloxone hydrochloride.

22. The pharmaceutical formulation of claim 1, wherein the formulation is in the form of a tablet.

23. The pharmaceutical formulation of claim 1, wherein the matrix is not based on a polymethacrylate.

24. The pharmaceutical formulation of claim 1, wherein the matrix does not comprise a relevant amount of a hydroxyalkylcellulose.

25. The pharmaceutical formulation of claim 1, wherein the sustained, invariant, and independent release characteristics of the matrix are determined by the ethylcellulose and the at least one fatty alcohol.

26. An oral pharmaceutical formulation comprising: at least one opioid agonist selected from oxycodone and pharmaceutically acceptable salts thereof; at least one opioid antagonist selected from naloxone and pharmaceutically acceptable salts thereof; and a diffusion matrix containing the at least one opioid agonist and the at least one opioid antagonist and comprising ethylcellulose and at least one fatty alcohol; wherein the matrix is configured to provide sustained, invariant, and independent release of the opioid agonist and the opioid antagonist; and wherein ethylcellulose is present in 1-15% by weight of the total formulation.

27. The pharmaceutical formulation of claim 26, wherein the fatty alcohol is selected from lauryl alcohol, myristyl alcohol, stearyl alcohol, cetylstearyl alcohol, ceryl alcohol, and cetyl alcohol.

28. The pharmaceutical formulation of claim 26, wherein the fatty alcohol is stearyl alcohol.

29. The pharmaceutical formulation of claim 26, wherein the opioid agonist is oxycodone hydrochloride.

30. The pharmaceutical formulation of claim 26, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 5 to 50 mg.

31. The pharmaceutical formulation of claim 26, wherein the opioid antagonist is naloxone hydrochloride.

32. The pharmaceutical formulation of claim 26, wherein the naloxone or pharmaceutically acceptable salt thereof is present in an amount ranging from 1 to 40 mg.

33. The pharmaceutical formulation of claim 26, wherein: the opioid agonist is oxycodone hydrochloride; and the opioid antagonist is naloxone hydrochloride.

34. The pharmaceutical formulation of claim 26, wherein: the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 10 to 150 mg; and the naloxone or pharmaceutically acceptable salt thereof is present in an amount ranging from 1 to 50 mg.

35. The pharmaceutical formulation of claim 34, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 10 to 80 mg.

36. The pharmaceutical formulation of claim 26, wherein the oxycodone or pharmaceutically acceptable salt thereof is present in an amount ranging from 5 to 50 mg.

37. The pharmaceutical formulation of claim 26, wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio ranging from 25:1 to 1:1.

38. The pharmaceutical formulation of claim 26, wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio ranging from 5:1 to 1:1.

39. The pharmaceutical formulation of claim 26, wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio of 5:1, 4:1, 3:1, 2:1, or 1:1.

40. The pharmaceutical formulation of claim 26, wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio of 2:1.

41. The pharmaceutical formulation of claim 26, wherein the ethylcellulose is present in 3-12% by weight of the total formulation.

42. The pharmaceutical formulation of claim 26, wherein the ethylcellulose is present in 5-9% by weight of the total formulation.

43. The pharmaceutical formulation of claim 26, wherein the fatty alcohol is present in 15-20% by weight of the total formulation.

44. The pharmaceutical formulation of claim 26, wherein the fatty alcohol is present in 10-25% by weight of the total formulation.

45. The pharmaceutical formulation of claim 26, wherein the fatty alcohol is stearyl alcohol and is present in 10-25% by weight of the total formulation; and the oxycodone or pharmaceutically acceptable salt thereof and is present in an amount ranging from 10 to 80 mg; and wherein the oxycodone or pharmaceutically acceptable salt thereof and the naloxone or pharmaceutically acceptable salt thereof are present in a weight ratio of 2:1.

46. The pharmaceutical formulation of claim 45, wherein: the opioid agonist is oxycodone hydrochloride; and the opioid antagonist is naloxone hydrochloride.

47. The pharmaceutical formulation of claim 26, wherein the formulation is in the form of a tablet.

48. The pharmaceutical formulation of claim 26, wherein the matrix is not based on a polymethacrylate.

49. The pharmaceutical formulation of claim 26, wherein the matrix does not comprise a relevant amount of a hydroxyalkylcellulose.

50. The pharmaceutical formulation of claim 26, wherein the sustained, invariant, and independent release characteristics of the matrix are determined by the ethylcellulose and the at least one fatty alcohol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc